Mo.Re.


Mo.Re. (Molecular Response) is multi-gene assay developed to provide an insight to the tumor’s biology of each patient.
Understanding the unique biology of each patient’s tumor can assist in providing individualized treatment options. The development of a new technology called Next Generation Sequencing or NGS, allows us today to analyze multiple genes from the same sample simultaneously.

ORDER NOW

This breakthrough technology along with cloud computing and bioinformatics work together in order to analyze massive volumes of data from the patients’ genome and transform it in an actionable report providing information on three main categories of results which are:

  • On-label drugs- Drugs approved for this patient’s tumor type.
  • Off-label drugs- Drugs not approved for this patient’s tumor type but approved for a different tumor type.
  • Clinical trials- Provide information on ongoing clinical trials based on this patient’s biology.

Why choose Mo.Re?

Mo.Re. is a widely validated assay that has been selected by the National Cancer Institute in the United States, as the assay of choice for stratifying more than 3000 patients that participate in the MATCH (Molecular Analysis for Therapy Choice) Clinical Trial to assign to them targeted treatments.  MATCH is the first multi-centric clinical study  where the targeted therapeutic approach is based on the molecular pathway analysis of the tumor, independently of the organ of origin. Mo.Re. is designed to help physicians select the appropriate targeted treatments for their patients and avoid the toxicity and other side effects of chemotherapy, especially in cases where a conventional therapy  has already been used with limited response and in some cases even resistance.

Who should be tested?

Mo.Re is designed in order to allow you and your physician to select which is the optimal targeted treatment based on your unique tumor biology.

This test is designed for the following cases:

  • Initial treatment plan is completed and more treatment options are needed.
  • Tumors without an established “gold standard” treatment.
  • Tumors that are aggressive and do not respond to standard treatment.
  • Rare tumors.
  • Tumor types with many targeted treatment options available such as lung cancer.

Table of Genes

147 Gene Alterations
AKT1 CDK12 FANCA IDH2 MSH2 PIK3CA RICTOR
AKT2 CDK2 FANCD2 IGF1R MSH6 PIK3CB RNF43
AKT3 CDK4 FANCI JAK1 MTOR PIK3R1 ROS1
ALK CDK6 FBXW7 JAK2 MYC PMS2 SETD2
AR CDKN1B FGF19 JAK3 MYCL POLE SF3B1
ARAF CDKN2A FGF3 KDR MYCN PPARG SLX4
ARID1A CDKN2B FGFR1 KIT MYD88 PPP2R1A SMAD4
ATM CHEK1 FGFR2 KNSTRN NBN PTCH1 SMARCA4
ATR CHEK2 FGFR3 KRAS NF1 PTEN SMARCB1
ATRX CREBBP FGFR4 MAGOH NF2 PTPN11 SMO
AXL CSF1R FLT3 MAP2K1 NFE2L2 RAC1 SPOP
BAP1 CTNNB1 FOXL2 MAP2K2 NOTCH1 RAD50 SRC
BRAF DDR2 GATA2 MAP2K4 NOTCH2 RAD51 STAT3
BRCA1 EGFR GNA11 MAPK1 NOTCH3 RAD51B STK11
BRCA2 ERBB2 GNAQ MAX NRAS RAD51C TERT
BTK ERBB3 GNAS MDM2 NTRK1 RAD51D TOP1
CBL ERBB4 H3F3A MDM4 NTRK2 RAF1 TP53
CCND1 ERCC2 HIST1H3B MED12 NTRK3 RB1 TSC1
CCND2 ESR1 HNF1A MET PALB2 RET TSC2
CCND3 ESR1 HRAS MLH1 PDGFRA RHEB U2AF1
CCNE1 EZH2 IDH1 MRE11A PDGFRB RHOA XPO1
51 fusion transcripts
AKT2 ALK AR AXL BRAF BRCA1 BRCA2
CDKN2A EGFR ERBB2 ERBB4 ERG ESR1 ETV1
ETV4 ETV5 FGFR1 FGFR2 FGFR3 FGR FLT3
JAK2 KRAS MDM4 MET MYB MUBL1 NF1
NOTCH1 NOTCH4 NRG1 NTRK1 NTRK2 NTRK3 NUTM1
PDGFRA PDGFRB PIK3CA PPARG PRKACA PRKACB PTEN
RAD51B RAF1 RB1 RELA RET ROS1 RSPO2
RSPO3 TERT          

Clinical Utility

Mo.Re. provides valuable information that can be utilized to select the optimal targeted treatment for patients. By analyzing many genes at the same time it provides a detailed blueprint of the biology of the tumor, which is used by the treating physician to design the patient’s treatment plan.

Actionable information in almost 80% of the time

Genekor Pie Chart

73% of the actionable cases will get at least one treatable mutation (on-label or off-label)

Genekor Pie Chart

What you get

Report

An individualized report that summarizes the findings of biology of your tumor is provided to you and your physician. <

Support

GeneKor takes care of all the logistics in order for your sample to arrive to our laboratory safely.

Interpretation

Our team of experts is here to interpret your results to you and your treating physician.

FAQS

Result Information

How to get Started

1

Order the test

Ask your physician if you are eligible for the Mo.Re. test

2

Sample requirement

Tissue from surgery or biopsy which is embedded in paraffin (FFPET) iis required for this test. Your sample will be collected per your physicans' instructions

3

Analysis Process

Your sample will arrive to our accredited laboratory and your report will be generated and released to you and your physician in 15 working days

4

Reporting

Your report will electronically released to your physician via email and/or uplaoded to our secure portal, and to you via email or mail

Technical Info

Mo.Re. is designed in order to achieve the highest sensitivity and specificity. All findings are classified using the most reliable and updated databases and in silico analysis algorithms. Advanced Next Generation Sequencing technology, also known as NGS, is used to fully analyze a panel of genes that are related to targeted treatments. The assay analyzes both DNA and RNA and looks at all possible gene alterations.

How to order

Our dedicated Client Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.

Please click here to see the specimen preparation and shipping instructions

If you would like to send us your sample,

contact us in order to arrange for all the logistics.

Please click here

Download Forms

you are already aware of the process of sending a sample, in order to download all the related forms.

Please click here